Chargement en cours...
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the goal and expectation for most patients. More recently, treatment-free remission (TFR) has entered mainstream pract...
Enregistré dans:
| Publié dans: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6246017/ https://ncbi.nlm.nih.gov/pubmed/30504306 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|